Introduction. Chronic lymphocytic leukaemia (CLL) is the most common type of leukaemia in adults and is characterised by marked phenotypic heterogeneity and variable risk profiles.
The objective of the study. The objective of the study was to investigate the association between markers of oxidative damage and unfavourable cytogenetic aberrations in the context of routinely used biochemical parameters in patients with CLL.
Material and methods. A total of 39 individuals were enrolled and divided into three groups: 10 healthy controls, 11 asymptomatic untreated CLL patients, and 18 patients receiving targeted therapy (venetoclax or ibrutinib). Serum prooxidant status was assessed using the d-ROMs test. Serum levels of protein carbonyls, advanced oxidation protein products (AOPP), and 8-hydroxy-2′-deoxyguanosine (8-OHdG) were measured using enzyme-linked immunosorbent assays.
Results. Serum triglyceride levels were significantly higher in patients receiving targeted therapy than in controls (p=0.003) and were also higher in patients with del(17p) than in those with del(11q) (p=0.019). Total cholesterol concentrations were significantly lower in patients with CLL than in healthy controls, particularly among treated patients (p=0.016). No statistically significant differences were observed in oxidative damage markers between patients and controls. However, serum protein carbonyl levels were significantly elevated in patients harbouring del(17p) compared with those without this aberration (p=0.013).
Conclusions. Elevated serum protein carbonyl levels in CLL patients with del(17p) may contribute to poorer clinical outcomes. Alterations in lipid parameters, including higher triglyceride and lower total cholesterol levels, indicate disease-related changes in lipid metabolism. Larger studies are needed to validate the combined use of oxidative stress markers and cytogenetic abnormalities for predicting disease progression.
Keywords: oxidative stress, chromosome aberrations, lipid metabolism, chronic lymphocytic leukaemia.
The objective of the study. The objective of the study was to investigate the association between markers of oxidative damage and unfavourable cytogenetic aberrations in the context of routinely used biochemical parameters in patients with CLL.
Material and methods. A total of 39 individuals were enrolled and divided into three groups: 10 healthy controls, 11 asymptomatic untreated CLL patients, and 18 patients receiving targeted therapy (venetoclax or ibrutinib). Serum prooxidant status was assessed using the d-ROMs test. Serum levels of protein carbonyls, advanced oxidation protein products (AOPP), and 8-hydroxy-2′-deoxyguanosine (8-OHdG) were measured using enzyme-linked immunosorbent assays.
Results. Serum triglyceride levels were significantly higher in patients receiving targeted therapy than in controls (p=0.003) and were also higher in patients with del(17p) than in those with del(11q) (p=0.019). Total cholesterol concentrations were significantly lower in patients with CLL than in healthy controls, particularly among treated patients (p=0.016). No statistically significant differences were observed in oxidative damage markers between patients and controls. However, serum protein carbonyl levels were significantly elevated in patients harbouring del(17p) compared with those without this aberration (p=0.013).
Conclusions. Elevated serum protein carbonyl levels in CLL patients with del(17p) may contribute to poorer clinical outcomes. Alterations in lipid parameters, including higher triglyceride and lower total cholesterol levels, indicate disease-related changes in lipid metabolism. Larger studies are needed to validate the combined use of oxidative stress markers and cytogenetic abnormalities for predicting disease progression.
Keywords: oxidative stress, chromosome aberrations, lipid metabolism, chronic lymphocytic leukaemia.
Address for correspondence: Viktoriya VARBANOVA
Department of Medical Physics and Biophysics, Medical University – Pleven
Address: 1 Kliment Ohridski St., 5800 Pleven, Bulgaria
E-mail address: viki_varbanova@abv.bg
Department of Medical Physics and Biophysics, Medical University – Pleven
Address: 1 Kliment Ohridski St., 5800 Pleven, Bulgaria
E-mail address: viki_varbanova@abv.bg
